BioCentury | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

...of AXL and c-Mer proto-oncogene tyrosine kinase (MERTK) (see BioCentury Innovations, Dec. 15, 2016) . Jennie Walters BGB324 HuMax-AXL-ADC TP-0903 BerGenBio...
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...AML Phase I Qurient Co. Ltd. (KOSDAQ:115180) Q-4 AXL inhibitor Cancer Preclinical Tolero Pharmaceuticals Inc. TP-0903...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Cancer

...biologic (CAB) targeting AXL, in preclinical testing to treat solid tumors. Tolero Pharmaceuticals Inc. has TP-0903...
...Oct. 4, 2016 doi:10.1126/scisignal.aaf8175 CONTACT: Ruby Yun-Ju Huang, National University of Singapore, Singapore email: ruby_yj_huang@nuhs.edu.sg Esme Gaisford BGB324 CAB-AXL-ADC TP-0903 BioAtla...
Items per page:
1 - 3 of 3